© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Lung Cancer
Sabari Examines Frontline and Second-Line Treatment Options in NSCLC
May 24, 2020
Joshua K. Sabari, MD, goes through treatment options in the frontline and second-line for patients with non–small cell lung cancer in a Targeted Oncology case-based peer perspectives live discussion.
Neoadjuvant Atezolizumab With Chemotherapy Feasible in Advanced NSCLC
May 24, 2020
"Our trial, together with ongoing randomized trials, provides more evidence on the risks and benefits of immunotherapy as a neoadjuvant treatment, and could help to answer questions regarding the optimal duration, best surrogate endpoint, and best predictive biomarkers for treatment."
Gerber Addresses the Role of Mutations and Treatment in NSCLC at Different Stages
May 23, 2020
In a Targeted Oncology case-based peer perspectives live discussion, David Gerber, MD, addresses the role of biomarkers in guiding treatment decisions for patients with non–small cell lung cancer based on a patient scenario.
FDA Approves Brigatinib as Frontline Treatment of ALK-Positive Metastatic NSCLC
May 22, 2020
The FDA has granted approval to brigatinib for the frontline treatment of patients with ALK-positive metastatic non–small cell lung cancer, as detected by an FDA-approved test.
FDA Approves Atezolizumab Monotherapy in Advanced PD-L1-High NSCLC
May 18, 2020
Atezolizumab has received its fifth indication in NSCLC as treatment of adult patients with metastatic non–small cell lung cancer who have high PD-L1 expression.
BMI May Stratify Clinical Trials to Measure Survival With Immunotherapy in NSCLC
May 18, 2020
A study found correlation between body mass index in patients with non–small cell lung cancer treated with atezolizumab and improved survival outcomes.
FDA Grants Breakthrough Designation to Trastuzumab Deruxtecan for HER2+ mNSCLC
May 18, 2020
"Today’s news is very welcome as we continue to evaluate the potential of Enhertu to help patients with this devastating type of lung cancer. Targeted treatments and immunotherapies are demonstrating tremendous advancements, but there remains an unmet medical need for patients with HER2 mutations who are not benefiting from such therapies or for those whose cancer continues to progress."
FDA Approves Nivolumab/Ipilimumab Combo for Advanced PD-L1+ NSCLC
May 15, 2020
The combination of the combination of nivolumab and ipilimumab is now approved by the FDA for the treatment of metastatic or recurrent non–small cell lung cancer with PD-L1 expression greater than 1%...
I/O Agent Demonstrates Lasting Clinical Benefit With or Without Pembrolizumab in Frontline NSCLC
May 14, 2020
"...These results leave us increasingly confident that ADXS-503 has the potential to restore or enhance sensitivity to checkpoint inhibitors..."
Oncogene Identification and Treatment Advances Guide Lung Cancer Meeting
May 13, 2020
With the identification of new oncogenes leading to the development of drugs that target mutations, lung cancer can now be considered a treatable disease. In addition to advances in therapy, improved tumor testing can help the oncologist develop a personalized approach to treating patients.